Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
10C4-B10
- Development stage
- Preclinical
- Lead developer
- Fred Hutchinson Cancer Research Institute
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
10C4-B10 is a boron-cage-conjugated murine monoclonal antibody targeting CD123 (interleukin-3 receptor alpha chain), developed by researchers at the Fred Hutchinson Cancer Research Center. The antibody clone 10C4 is conjugated with isothiocyanatophenethyl-ureido-closo-decaborate(2-) (B10), which serves as a stable linker for labeling with the alpha-particle emitting radionuclide astatine-211 (211At). This radioimmunotherapy (RIT) approach is designed to deliver high-energy radiation specifically to CD123-positive cells, which are widely expressed in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other hematologic malignancies, including leukemic stem cells. Preclinical studies have demonstrated that 211At-labeled 10C4-B10 effectively reduces tumor burden and prolongs survival in leukemia xenograft models.
- Other names
- B10-conjugated anti-CD123 mAbB-10-conjugated anti-CD123 mAbB 10-conjugated anti-CD123 mAb123-10C4-B10
02
Targets
IL3RA (Interleukin 3 Receptor)
Beyond the preview
Go deeper on 10C4-B10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 10C4-B10.